个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Zhang Xiaoshuai[1] ; Xu Na[2] ; Yang Yunfan[3] ; Lin Hai[4] ; Liu Bingcheng[5] ; Du Xin[6] ; Liu Xiaoli[2] ; Liang Rong[7] ; Chen Chunyan[8] ; Huang Jian[9] ; Zhu Huanling[3] ; Pan Ling[3] ; Wang Xiaodong[10] ; Li Guohui[11] ; Liu Zhuogang[12] ; Zhang Yanqing[13] ; Liu Zhenfang[14] ; Hu Jianda[15] ; Liu Chunshui[4] ; Li Fei[16] ; Yang Wei[12] ; Meng Li[17] ; Han Yanqiu[18] ; Lin Li'e[19] ; Zhao Zhenyu[19] ; Tu Chuanqing[20] ; Zheng Caifeng[20] ; Bai Yanliang[21] ; Zhou Zeping[22] ; Chen Suning[23] ; Qiu Huiying[23] ; Yang Lijie[11] ; Sun Xiuli[24] ; Sun Hui[25] ; Zhou Li[26] ; Liu Zelin[27] ; Wang Danyu[27] ; Guo Jianxin[28] ; Pang Liping[29] ; Zeng Qingshu[30] ; Suo Xiaohui[31] ; Zhang Weihua[32] ; Zheng Yuanjun[32] ; Zhang Yanli[33] ; Li Weiming[34] ; Jiang Qian[1,35] ;
机构： [1]Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. [2]Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China. [3]Department of Hematology, Institute of Hematology, West China Hospital, Sichuan University, Sichuan, China. [4]Department of Hematology, The First Hospital of Jilin University, Jilin, China. [5]National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjing, China. [6]Department of Hematology, The Second People’s Hospital of Shenzhen, The First Affiliated Hospital of Shenzhen University, Shenzhen, China. [7]Department of Hematology, Xijing Hospital, Airforce Military Medical University, Xi’an, China. [8]Department of Hematology, Qilu Hospital of Shandong University, Jinan, China. [9]Department of Hematology, The First Affiliated Hospital of Zhejiang University, College of Medicine, Zhejiang University. Department of Hematology, The Fourth Affiliated Hospital of Zhejiang University, College of Medicine, Zhejiang University. Zhejiang Provincial Clinical Research Center for Haematological Disorders, Zhejiang, China. [10]Department of Hematology, Sichuan Academy of Medical Sciences Sichuan Provincial People’s Hospital, Sichuan, China. [11]Department of Hematology, Xi’an international medical center hospital, Xi’an, China. [12]Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, China. [13]Department of Hematology, The Second Affiliated Hospital of Harbin Medical University, Harbin, China. [14]Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Guangxi, China. [15]Department of Hematology, Fujian Medical University Union Hospital, Fujian, China. [16]Center of Hematology, The First Affiliated Hospital of Nanchang University, Nanchang, China. [17]Department of Hematology, Tongji Hospital of Tongji Medical College, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China. [18]Department of Hematology, The Affiliated Hospital of Inner Mongolia Medical University, Inner Mongolia, China. [19]Department of Hematology, Hainan General Hospital, Hainan, China. [20]Department of Hematology, Shenzhen Baoan Hospital, Shenzhen University Second Affiliated Hospital, Shenzhen, China. [21]Department of Hematology, Henan Provincial People’s Hospital [22]Zhengzhou University People’s Hospital, Henan, China. [22]Department of Hematology, The Second Hospital Affiliated to Kunming Medical University, Kunming, China. [23]National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Institute of Blood and Marrow Transplantation of Soochow University, Soochow, China. [24]Department of Hematology, The First Affiliated Hospital of Dalian Medical University, Dalian, China. [25]Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. [26]Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. [27]Department of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital, Nanshan Hospital, Shenzhen, China. [28]Department of Hematology, The Second Affiliated Hospital of Fujian Medical University, Fujian, China. [29]Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, China. [30]Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Anhui, China. [31]Department of Hematology, Handan Central Hospital, Handan, China. [32]Department of Hematology, First Hospital of Shanxi Medical University, Shanxi, China. [33]Department of Hematology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Henan, China. [34]Department of Hematology, Union hospital, Tongji Medical college, Huazhong University of Science and Technology, Wuhan, China. [35]Peking University People’s Hospital, Qingdao, China.
出处：
DOI： 10.1016/j.clml.2024.02.008
ISSN：

关键词： CML Outcomes Propensity-score matching (PSM) Second-generation tyrosine-kinase inhibitor (2G-TKI) Therapy responses

摘要：
There are limited data comprehensively comparing therapy responses and outcomes among nilotinib, dasatinib, flumatinib and imatinib for newly diagnosed chronic-phase chronic myeloid leukemia in a real-world setting.Data from patients with chronic-phase CML receiving initial a second-generation tyrosine-kinase inhibitor (2G-TKI, nilotinib, dasatinib or flumatinib) or imatinib therapy from 77 Chinese centers were retrospectively interrogated. Propensity-score matching (PSM) analyses were performed to to compare therapy responses and outcomes among these 4 TKIs.2,496 patients receiving initial nilotinib (n = 512), dasatinib (n = 134), flumatinib (n = 411) or imatinib (n = 1,439) therapy were retrospectively interrogated in this study. PSM analyses indicated that patients receiving initial nilotinib, dasatinib or flumatinib therapy had comparable cytogenetic and molecular responses (p = .28-.91) and survival outcomes including failure-free survival (FFS, p = .28-.43), progression-free survival (PFS, p = .19-.93) and overall survival (OS) (p values = .76-.78) but had significantly higher cumulative incidences of cytogenetic and molecular responses (all p values < .001) and higher probabilities of FFS (p < .001-.01) than those receiving imatinib therapy, despite comparable PFS (p = .18-.89) and OS (p = .23-.30).Nilotinib, dasatinib and flumatinib had comparable efficacy, and significantly higher therapy responses and higher FFS rates than imatinib in newly diagnosed CML patients. However, there were no significant differences in PFS and OS among these 4 TKIs. These real-world data may provide additional evidence for routine clinical assessments to identify more appropriate therapies.Copyright © 2024 Elsevier Inc. All rights reserved.

基金：
National Natural Science Foundation of China (No. 81970140 and No. 82370161). Funded by the National Nature Science Foundation of China (No. 81970140 and No. 82370161).
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 4 区 医学
小类 | 4 区 血液学 4 区 肿瘤学
最新[2023]版：
大类 | 4 区 医学
小类 | 4 区 血液学 4 区 肿瘤学
JCR分区：
出版当年[2023]版：
Q2 HEMATOLOGY Q3 ONCOLOGY
最新[2023]版：
Q2 HEMATOLOGY Q3 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2023版]

第一作者：
第一作者机构： [1]Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
共同第一作者：
通讯作者：
通讯机构： [1]Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China. [35]Peking University People’s Hospital, Qingdao, China.
推荐引用方式(GB/T 7714)：
Zhang Xiaoshuai,Xu Na,Yang Yunfan,et al.Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study[J].CLINICAL LYMPHOMA MYELOMA & LEUKEMIA.2024,24(6):e257-e266.doi:10.1016/j.clml.2024.02.008.
APA：
Zhang Xiaoshuai,Xu Na,Yang Yunfan,Lin Hai,Liu Bingcheng...&Jiang Qian.(2024).Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study.CLINICAL LYMPHOMA MYELOMA & LEUKEMIA,24,(6)
MLA：
Zhang Xiaoshuai,et al."Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study".CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 24..6(2024):e257-e266

相关文献

[1]Effects of general anesthesia versus local anesthesia in primary hepatocellular carcinoma patients presenting for thermal ablation surgery: a multiple center retrospective cohort study with propensity score matching [2]Lymph node dissection of station 8 improves the survival of T&#x2264;3 cmN0M0 lung adenocarcinoma patients [3]A novel T1a/b classification for testicular cancer: not only seminoma [4]Copper and Melanoma Risk: Results from NHANES 2007-2018 and Mendelian Randomization Analyses [5]Loss of PRMT7 reprograms glycine metabolism to selectively eradicate leukemia stem cells in CML. [6]Responses to Crizotinib therapy in five patients with non-small-cell lung cancer who tested FISH negative and Ventana immunohistochemistry positive for ALK fusions [7]Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance [8]Prevalence and clinical significance of pleural effusion in patients with acute pulmonary embolism: a retrospective study [9]Treatment of chronic-phase chronic myeloid leukemia in patients randomized to dasatinib or imatinib after suboptimal responses to three months of imatinib therapy: final 5-year results from DASCERN [10]Analysis of a registry database for esophageal cancer from high-volume centers in China.

资源点击量：43377 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号